TrimRX
US$ 27.72
glp 1 drug mechanism of action GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes The Impact of GLP-1 Receptor
Description
2017;26(2):343352 e342
88.9%), and therapeutic inertia was observed in only 45 individuals (11.1%) (Table 6)
Montrose-Rafizadeh et al., 1994
Larger peptide-based compounds, like GLP-1 medications, cannot get through without special technology like microneedles or chemical enhancers
Some studies paint an even starker picture, showing four times more retained gastric contents (13.6% versus 2.3%) [1]
Conclusions, limitations, and future directions The success of GLP-1 medicines as a breakthrough in medical obesity treatment marks the culmination of over 4 decades of research into GLP-1 physiology and pharmacology
